NASH

ContraVir Pharmaceuticals Inc (NASDAQ: CTRV) shares were rallying Monday on positive news related to its non-alcoholic steatohepatitis, or NASH, drug. ContraVir, which came under pressure Friday following news of an erroneous SEC filing, said Monday ahead of the market open that findings...

Shares of the nano-cap, thinly traded biotech ContraVir Pharmaceuticals Inc (NASDAQ: CTRV) were trading nearly 150-percent higher Thursday.  What Happened ContraVir, which focuses on therapies for liver diseases arising from non-alcoholic steatohepatitis, or NASH, as well as chronic viral...

Gilead Sciences, Inc. (NASDAQ: GILD), which was once considered one of the front-runners in the race to develop a drug for non-alcoholic steatohepatitis, or NASH, has been facing setback after setback. What Happened A little more than two months after it reported failed results for a late-stage...

Shares of microcap biotech Conatus Pharmaceuticals Inc (NASDAQ: CNAT) are heading crashing following the release of results from a midstage trial of its non-alcoholic steatohepatitis candidate. What Happened Conatus, which is developing emricasan along with Novartis AG (NYSE: NVS) for treating...

Intercept Pharmaceuticals Inc (NASDAQ: ICPT) — which is a frontrunner along with Gilead Sciences, Inc. (NASDAQ: GILD) in the non-alcoholic steatohepatitis drug development race — reported positive top-line results Tuesday for a late-stage study of its pipeline asset Ocaliva,...

With Gilead Sciences, Inc. (NASDAQ: GILD)'s NASH setback, Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT)'s Ocaliva, which is being evaluated in a late-stage study for NASH with fibrosis, is taking the spotlight.  A clinical readout from the trial is expected this quarter. The...

Lipocine Inc (NASDAQ: LPCN) shares were skyrocketing Thursday following the release of results from a study evaluating LPCN 1144, its pipeline asset for non-alcoholic steatohepatitis, or NASH. What Happened Lipocine announced Thursday that eight-week top-line, interim results from an ongoing...

The biotechnology sector remains highly competitive, and investors willing to take on a stock with a high-risk, high-growth profile may want to consider Gilead Sciences, Inc. (NASDAQ: GILD), according to Raymond James. The Analyst Raymond James' Steven Seedhouse initiated coverage of...

Shares of Intercept Pharmaceuticals Inc (NASDAQ: ICPT) lost around one quarter of their value Thursday and another 7 percent early Friday morning in reaction to a concerning U.S. Food and Drug Administration letter sent to doctors regarding its liver treatment product called Ocaliva for the...

Shares of Intercept Pharmaceuticals Inc (NASDAQ: ICPT) jumped nearly 10 percent early Friday morning after the company provided an update on an ongoing clinical trial. Intercept is a biopharmaceutical company that focuses on developing and commercializing therapeutics to treat progressive non-viral...

Non-alcoholic steatohepatitis (NASH) is a type of non-alcoholic fatty liver disease (NAFLD), a condition in which fat builds up in a person's liver. As noted by the National Institute of Diabetes and Digestive and Kidney Diseases, there are no approved medicines to treat NAFLD and NASH. In a...

Allergan plc Ordinary Shares (NYSE: AGN)'s acquisition of Tobira Therapeutics Inc (NASDAQ: TBRA) has some analysts wondering: if Allergan is willing to pay a massive 500 percent premium for Tobira, then what could possibly come next? Barrons cited Kevin Kedra, an analyst at Gabelli, who...

Allergan plc Ordinary Shares (NYSE: AGN) paid a hefty premium of 159 percent to acquire Vitae Pharmaceuticals Inc (NASDAQ: VTAE) last week, but that figure pales in comparison to the premium attached to its acquisition of Tobira Therapeutics Inc (NASDAQ: TBRA). Allergan will pay $533 million in...

Shares of Tobira Therapeutics Inc (NASDAQ: TBRA) soared higher by more than 700 percent on Tuesday after the company was acquired by Allergan plc Ordinary Shares (NYSE: AGN). The massive premium Allergan is paying in Tobira's stock price has many investors questioning if any of Tobira's peers are...

Tobira Therapeutics Inc (NASDAQ: TBRA), a clinical-stage bio-pharmaceutical company that focuses on the development of therapies to treat non-alcoholic steatohepatitis (NASH) and other liver diseases, soared higher by more than 760 percent on Tuesday after the company agreed to sell itself to...